Alnylam Pharmaceuticals, Inc.

Thank you for standing by and welcome to the Allen Island Pharmaceuticals first quarter 2021 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you'll need to press star 1 on your telephone. As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications. Please go ahead.

Good morning. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today on the phone are John Maragonori, Chief Executive Officer, Toba Tangular, Chief Commercial Officer, Akshay Vaishnav, President of R&D, Jeff Fulton, Chief Financial Officer, and Yvonne Greenstreet, President and Chief Operating Officer. For those of you participating via conference call, the accompanying slides can be accessed by going to the events section of the investors page of our website, investors.alnylam.com slash events. During today's call, as outlined in slide two, John will provide some introductory remarks in general context. Togo will provide an update on our global commercial progress. Akshay will review recent clinical and preclinical updates. Jesse will review our financials. And Yvonne will provide a brief summary of upcoming milestones before opening the call to your questions. I'd like to remind you that this call will contain remarks concerning LNILAM's future expectations and plans and prospects. which constitute forward-looking statements for the purposes of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent annual report on file with the SEC. In addition, any forward-looking statements represent our views only as to the dates of this recording and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update such statements. With that, I'd like to turn the call over to John. John?

Thanks, Christine, and thank you, everyone, for joining the call today. 2021 is off to a great start for Alnylam, with four approved RNAi therapeutics now helping patients around the world, and more in our pipeline poised to do the same in the coming years. To start, our teams delivered steady, ongoing commercial execution and continued revenue growth, including 13% quarterly growth for Ampatro with our first triple-digit revenue quarter and an impressive initial uptake for Oxlumo in its first full quarter on the market. On the pipeline side, the full positive results from the Helios A phase 3 study of Butresaran were presented last week, and we announced that we have filed an NDA for Butresaran with the FDA and bringing us a step closer to the potential approval of this important asset in our TTR franchise. We're also excited to have announced today that we expect the Helios B study of vitreous saran in ATTR patients with cardiomyopathy to complete enrollment later this year, earlier than previously anticipated. Regarding our broader corporate strategy, we announced in January a new set of five-year goals, Alnylam P to the 5th by 25, highlighting a bold vision for Alnylam with transformative medicines in both rare and common diseases for patients around the world, supported by additional growth through label expansion, a robust and high-yielding pipeline of first and or best-in-class product candidates from our organic product engine, exceptional financial performance with over 40% revenue CAGR through year-end 2025, and sustainable non-GAAP profitability achieved within the period. At Al Malam, we continue to be guided by our challenge-accepted philosophy, which underpins our commitment to tackling unprecedented and complex challenges, taking courageous action, and using our business as a force of good. As a result, we are extremely proud to release this quarter our first Corporate Responsibility Summary. As scientific pioneers, corporate leaders, and global citizens, Cal Milam has long been committed to using our business as a force of good, beyond our core mission of developing innovative medicine. If you haven't already, I encourage you to visit our website to review the exciting progress and commitments we've made. So with that, I'll now turn the call over to Tolga for a review of our commercial performance. Tolga?